CA2303069A1 - Traitement du stress et preconditionnement contre le stress - Google Patents
Traitement du stress et preconditionnement contre le stress Download PDFInfo
- Publication number
- CA2303069A1 CA2303069A1 CA 2303069 CA2303069A CA2303069A1 CA 2303069 A1 CA2303069 A1 CA 2303069A1 CA 2303069 CA2303069 CA 2303069 CA 2303069 A CA2303069 A CA 2303069A CA 2303069 A1 CA2303069 A1 CA 2303069A1
- Authority
- CA
- Canada
- Prior art keywords
- blood
- patient
- aliquot
- stress
- stressor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims description 39
- 210000004369 blood Anatomy 0.000 claims abstract description 127
- 239000008280 blood Substances 0.000 claims abstract description 127
- 230000005855 radiation Effects 0.000 claims abstract description 36
- 230000001590 oxidative effect Effects 0.000 claims abstract description 26
- 238000001356 surgical procedure Methods 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 230000036772 blood pressure Effects 0.000 claims abstract description 11
- 208000024891 symptom Diseases 0.000 claims abstract description 11
- 239000001301 oxygen Substances 0.000 claims abstract description 10
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 10
- 230000002829 reductive effect Effects 0.000 claims abstract description 9
- 208000028867 ischemia Diseases 0.000 claims description 40
- 210000000056 organ Anatomy 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 27
- 230000036760 body temperature Effects 0.000 claims description 25
- 210000002216 heart Anatomy 0.000 claims description 21
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 19
- 210000003734 kidney Anatomy 0.000 claims description 18
- 239000007789 gas Substances 0.000 claims description 14
- 108091000080 Phosphotransferase Proteins 0.000 claims description 11
- 102000020233 phosphotransferase Human genes 0.000 claims description 11
- 230000000302 ischemic effect Effects 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 230000037361 pathway Effects 0.000 claims description 9
- 230000002411 adverse Effects 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 6
- 230000003938 response to stress Effects 0.000 claims description 6
- 206010002091 Anaesthesia Diseases 0.000 claims description 5
- 238000001949 anaesthesia Methods 0.000 claims description 5
- 230000037005 anaesthesia Effects 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- 206010061216 Infarction Diseases 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 210000000601 blood cell Anatomy 0.000 claims description 4
- 230000007574 infarction Effects 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000007814 Unstable Angina Diseases 0.000 claims description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 206010002388 Angina unstable Diseases 0.000 claims description 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 7
- 229910001882 dioxygen Inorganic materials 0.000 abstract description 7
- 206010063837 Reperfusion injury Diseases 0.000 abstract description 6
- 238000010438 heat treatment Methods 0.000 abstract description 6
- 241000124008 Mammalia Species 0.000 abstract description 4
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 88
- 230000035882 stress Effects 0.000 description 64
- 238000000034 method Methods 0.000 description 56
- 239000007924 injection Substances 0.000 description 39
- 238000002347 injection Methods 0.000 description 39
- 230000008569 process Effects 0.000 description 38
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 26
- 238000012360 testing method Methods 0.000 description 16
- 230000006378 damage Effects 0.000 description 14
- 229940109239 creatinine Drugs 0.000 description 13
- 239000000523 sample Substances 0.000 description 12
- 230000010410 reperfusion Effects 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000035487 diastolic blood pressure Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000005587 bubbling Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000002530 ischemic preconditioning effect Effects 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000002254 renal artery Anatomy 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 206010062237 Renal impairment Diseases 0.000 description 2
- 206010063897 Renal ischaemia Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000009529 body temperature measurement Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000009532 heart rate measurement Methods 0.000 description 2
- 230000008642 heat stress Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 231100000857 poor renal function Toxicity 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002796 renal vein Anatomy 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- YKJYKKNCCRKFSL-RDBSUJKOSA-N (-)-anisomycin Chemical compound C1=CC(OC)=CC=C1C[C@@H]1[C@H](OC(C)=O)[C@@H](O)CN1 YKJYKKNCCRKFSL-RDBSUJKOSA-N 0.000 description 1
- YKJYKKNCCRKFSL-UHFFFAOYSA-N Anisomycin Natural products C1=CC(OC)=CC=C1CC1C(OC(C)=O)C(O)CN1 YKJYKKNCCRKFSL-UHFFFAOYSA-N 0.000 description 1
- 101000761770 Bombina maxima Kininogen-1c Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042209 Stress Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000013171 endarterectomy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008246 gaseous mixture Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001706 oxygenating effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Substances [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Dans le but de traiter les symptômes du stress, tels que l'hypertension artérielle chez les mammifères, et de préconditionner l'organisme de ces derniers afin qu'ils présentent moins de réactions négatives aux stress auxquels ils seront exposés ultérieurement, on injecte audit patient une petite quantité de son propre sang que l'on a préalablement prélevé et soumis en extracorporel à au moins un agent stressant, tel qu'un rayonnement ultraviolet, un environnement oxydant, un mélange d'ozone et d'oxygène ou un chauffage modéré, notamment un rayonnement ultraviolet entraînant un chauffage modéré. Les combinaisons particulièrement bénéfiques d'agents stressants sont l'application simultanée d'un rayonnement UV et d'un mélange gazeux d'ozone et d'oxygène, que l'on introduit par bullage dans l'échantillon de sang de façon à créer l'environnement oxydant, et l'application simultanée d'un rayonnement UV, d'un mélange gazeux d'ozone et d'oxygène et d'un chauffage modéré. Une utilisation spécifique de l'invention est le préconditionnement contre les lésions ischémiques dues à des perfusions répétées, avant une intervention chirurgicale par exemple.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5878297P | 1997-09-12 | 1997-09-12 | |
| US60/058,782 | 1997-09-12 | ||
| PCT/CA1998/000869 WO1999013890A1 (fr) | 1997-09-12 | 1998-09-11 | Traitement du stress et preconditionnement contre le stress |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2303069A1 true CA2303069A1 (fr) | 1999-03-25 |
Family
ID=22018893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2303069 Abandoned CA2303069A1 (fr) | 1997-09-12 | 1998-09-11 | Traitement du stress et preconditionnement contre le stress |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2303069A1 (fr) |
-
1998
- 1998-09-11 CA CA 2303069 patent/CA2303069A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6136308A (en) | Treatment of stress and preconditioning against stress | |
| CA2129630C (fr) | Methode d'accroissement de la concentration en oxyde nitrique dans le sang | |
| US6986888B1 (en) | Method for treating mammals with modified mammalian blood | |
| EP1011696B1 (fr) | Traitement du stress et preconditionnement contre le stress | |
| US6432399B1 (en) | Treatment of stress and preconditioning against stress | |
| US20020086064A1 (en) | Method of treating atherosclerosis | |
| EP1146885B1 (fr) | Pretraitement contre la mort des cellules | |
| NZ306395A (en) | Treatment of blood to remove symptoms of vascular disorders by elevation of temperature, ultraviolet radiation or treatment with an oxidative environment | |
| US7045124B1 (en) | Pre-conditioning against cell death | |
| CA2303069A1 (fr) | Traitement du stress et preconditionnement contre le stress | |
| HK1031322B (en) | Treatment of stress and preconditioning against stress | |
| ES2223503T3 (es) | Tratamiento de trastornos por reaccion de hipersensibilidad. | |
| CA2230836A1 (fr) | Induction de resistance aux stress ischemiques | |
| CA2218625A1 (fr) | Traitement du stress et conditionnement au prealable anti-stress | |
| CA2372624A1 (fr) | Methode amelioree pour traiter des mammiferes au moyen de sang modifie de mammifere | |
| CA2308105A1 (fr) | Traitement des carences en il-10 | |
| AU6252100A (en) | Endothelial lining effects and treatment of vasospastic disorders | |
| Delivoria-Papadopoulos et al. | 1374 CARBON MONOXIDE EFFECT ON BRAIN OXIDATIVE METABOLISM IN NEWBORN PIGLETS | |
| Curtis-Cohen et al. | 1370 LYSIS OF AORTIC THROMBUS WITH STREPTOKINASE | |
| Coulter et al. | 1369 BARBITURATE ANAESTHESIA REDUCES THE INCIDENCE OF INTRAVENTRICULAR HEMORRHAGE (IVH) IN THE BEAGLE PUPPY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20090911 |